Browsing by Subject "VIRUS-INFECTIONS"

Sort by: Order: Results:

Now showing items 1-3 of 3
  • Erra, Elina O.; Korhonen, Essi M.; Voutilainen, Liina; Huhtamo, Eili; Vapalahti, Olli; Kantele, Anu (2013)
  • Schneider, Julia; Hoffmann, Bernd; Fevola, Cristina; Schmidt, Marie Luisa; Imholt, Christian; Fischer, Stefan; Ecke, Frauke; Hoernfeldt, Birger; Magnusson, Magnus; Olsson, Gert E.; Rizzoli, Annapaola; Tagliapietra, Valentina; Chiari, Mario; Reusken, Chantal; Buzan, Elena; Kazimirova, Maria; Stanko, Michal; White, Thomas A.; Reil, Daniela; Obiegala, Anna; Meredith, Anna; Drexler, Jan Felix; Essbauer, Sandra; Henttonen, Heikki; Jacob, Jens; Hauffe, Heidi C.; Beer, Martin; Heckel, Gerald; Ulrich, Rainer G. (2021)
    The development of new diagnostic methods resulted in the discovery of novel hepaciviruses in wild populations of the bank vole (Myodes glareolus, syn. Clethrionomys glareolus). The naturally infected voles demonstrate signs of hepatitis similar to those induced by hepatitis C virus (HCV) in humans. The aim of the present research was to investigate the geographical distribution of bank vole-associated hepaciviruses (BvHVs) and their genetic diversity in Europe. Real-time reverse transcription polymerase chain reaction (RT-qPCR) screening revealed BvHV RNA in 442 out of 1838 (24.0%) bank voles from nine European countries and in one of seven northern red-backed voles (Myodes rutilus, syn. Clethrionomys rutilus). BvHV RNA was not found in any other small mammal species (n = 23) tested here. Phylogenetic and isolation-by-distance analyses confirmed the occurrence of both BvHV species (Hepacivirus F and Hepacivirus J) and their sympatric occurrence at several trapping sites in two countries. The broad geographical distribution of BvHVs across Europe was associated with their presence in bank voles of different evolutionary lineages. The extensive geographical distribution and high levels of genetic diversity of BvHVs, as well as the high population fluctuations of bank voles and occasional commensalism in some parts of Europe warrant future studies on the zoonotic potential of BvHVs.
  • Albinsson, Bo; Jääskeläinen, Anu E.; Värv, Kairi; Jelovšek, Mateja; GeurtsvanKessel, Corine; Vene, Sirkka; Järhult, Josef D.; Reusken, Chantal; Golovljova, Irina; Avšič-Županc, Tatjana; Vapalahti, Olli; Lundkvist, Åke (2020)
    Tick-borne encephalitis (TBE) is a potentially severe neurological disease caused by TBE virus (TBEV). In Europe and Asia, TBEV infection has become a growing public health concern and requires fast and specific detection. Aim: In this observational study, we evaluated a rapid TBE IgM test, ReaScan TBE, for usage in a clinical laboratory setting. Methods: Patient sera found negative or positive for TBEV by serological and/or molecular methods in diagnostic laboratories of five European countries endemic for TBEV (Estonia, Finland, Slovenia, the Netherlands and Sweden) were used to assess the sensitivity and specificity of the test. The patients' diagnoses were based on other commercial or quality assured in-house assays, i.e. each laboratory's conventional routine methods. For specificity analysis, serum samples from patients with infections known to cause problems in serology were employed. These samples tested positive for e.g. Epstein-Barr virus, cytomegalovirus and Anaplasma phagocytophilum, or for flaviviruses other than TBEV, i.e. dengue, Japanese encephalitis, West Nile and Zika viruses. Samples from individuals vaccinated against flaviviruses other than TBEV were also included. Altogether, 172 serum samples from patients with acute TBE and 306 TBE IgM negative samples were analysed. Results: Compared with each laboratory's conventional methods, the tested assay had similar sensitivity and specificity (99.4% and 97.7%, respectively). Samples containing potentially interfering antibodies did not cause specificity problems. Conclusion: Regarding diagnosis of acute TBEV infections, ReaScan TBE offers rapid and convenient complementary IgM detection. If used as a stand-alone, it can provide preliminary results in a laboratory or point of care setting.